The European Commission has approved Advicenne’s Sibnayal for the orphan disease distal renal tubular acidosis (dRTA). The approval came after the company voluntarily withdrew the orphan drug designation (ODD) it had received in June 2017 during its development of the drug after the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) requested more data.
The company told the Pink Sheet that withdrawing the ODD would enable it to make Sibnayal, also
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?